POMDOCTOR LIMITED (POM) is an Other Specialty Stores company listed on NASDAQ. In the last 30 days Quantisnow tracked 10 wire items for POM, including 6 press releases and news items and 4 SEC filings. The most recent was published Nov 11, 2026.
POM rankings
Financial highlights
Full financials- Revenue, FY2025
- CN¥399.91M
- Revenue growth
- +16.7%
- Net income, FY2025
- -CN¥212.58M
- Net margin
- -53.2%
- Free cash flow, FY2025
- -CN¥149.49M
- Cash
- CN¥9.58M
For fiscal 2025 (ended Dec 31, 2025), from SEC filings. Not investment advice.
News · 26 weeks390%
2026-05-172026-11-08
Mix2390d
- SEC Filings12(52%)
- Other11(48%)
Activity · 52 weeks6135 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- PRPOMDOCTOR LIMITED Highlights Real-World Data as a Strategic Foundation for AI-Enabled Healthcare SolutionsCompany emphasizes the expanding applications of real-world data in medical research, clinical decision-making, healthcare payment and personalized treatmentGUANGZHOU, China, Nov. 11, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (NASDAQ:POM), a digital healthcare company focused on advancing artificial intelligence ("AI")-enabled healthcare solutions, today highlighted the growing strategic importance of its real-world data ("RWD") assets in transforming healthcare delivery and decision-making, as well as the Company's initiatives to develop its RWD capabilities as a foundation for advancing predictive and data-driven healthcare solutions. As healthcare systems incre
- SECSEC Form 6-K filed by POMDOCTOR LIMITED6-K - POMDOCTOR Ltd (0001877971) (Filer)
- PRPOMDOCTOR LIMITED Regains Compliance with Nasdaq Bid Price RequirementGUANGZHOU, China, Nov. 6, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (NASDAQ:POM), a digital healthcare company focused on advancing AI-enabled healthcare solutions and predictive healthcare capabilities, today announced that on November 5, 2026, the Company received a letter (the "Compliance Letter") from The Nasdaq Stock Market LLC ("Nasdaq") informing the Company that it has regained compliance with the minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5450(a)(1). As a result, the hearing before the Nasdaq Hearings Panel originally scheduled for November 12, 2026 has been cancelled.As previously disclosed, on October 6, 2026, the Company
- SECSEC Form 6-K filed by POMDOCTOR LIMITED6-K - POMDOCTOR Ltd (0001877971) (Filer)
- PRPOMDOCTOR LIMITED Advances Strategic Evolution from Traffic Monetization to Value-Based Healthcare PaymentBuilding a Four-Tier Revenue Structure Across B2C Services, AI-Enabled Chronic Disease Management, B2B Healthcare Services, and Pharmaceutical RWS/RWDGUANGZHOU, China, Nov. 4, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (NASDAQ:POM), a digital healthcare company focused on advancing AI-enabled healthcare solutions, today provided an overview of its strategic evolution and business model transformation amid the rapid development of China's digital healthcare industry. Since its establishment in 2010, Pomdoctor has progressively evolved from the industry's early "traffic monetization" model toward a more diversified and value-oriented healthcare ecosystem, culminating
- SECSEC Form 6-K filed by POMDOCTOR LIMITED6-K - POMDOCTOR Ltd (0001877971) (Filer)
- PRPOMDOCTOR LIMITED Announces Receipt of Nasdaq Notifications Regarding Continued Listing RequirementsGUANGZHOU, China, Nov. 2, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (NASDAQ:POM), a digital healthcare company focused on advancing AI-enabled healthcare solutions and predictive healthcare capabilities, today announced that on October 28, 2026, it received two letters (the "Letters") from the Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") regarding deficiencies with respect to certain continued listing requirements of The Nasdaq Global Market. The first Letter notified the Company that, based upon the Company's MVLS for the 30 consecutive business days from September 16, 2026 through October 27, 2026, the Company no long
- PRPOMDOCTOR LIMITED Announces the Termination of Its ADR Program and Trade Class A Ordinary Shares on NasdaqGUANGZHOU, China, Oct. 19, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (NASDAQ:POM), a digital healthcare company focused on advancing artificial intelligence ("AI")-enabled healthcare solutions, today announced that it has commenced to terminate its American Depositary Receipt program (the "ADR Program"), including the termination of the related deposit agreement, as amended, and list the Company's Class A ordinary shares directly on The Nasdaq Stock Market LLC ("Nasdaq"). The termination was previously approved by the board of directors of Pomdoctor on September 3, 2026 and approved by the Company's shareholders on a non-binding advisory basis at the extraordinary
- SECSEC Form 6-K filed by POMDOCTOR LIMITED6-K - POMDOCTOR Ltd (0001877971) (Filer)
- PRPOMDOCTOR LIMITED Highlights the Shift from Reactive Treatment to Predictive HealthcareGUANGZHOU, China, Oct. 12, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (NASDAQ:POM), a digital healthcare company focused on advancing artificial intelligence ("AI")-enabled healthcare solutions, today highlighted its strategy to participate in the ongoing transformation of healthcare from a traditionally reactive model centered on treating illness after it occurs toward a more predictive and proactive approach to health management.For much of the past century, healthcare delivery has primarily followed an event-driven model in which patients seek medical care after symptoms emerge, physicians diagnose the condition, and treatment follows. While advances in medical
- SECSEC Form 6-K filed by POMDOCTOR LIMITED6-K - POMDOCTOR Ltd (0001877971) (Filer)
- PRPOMDOCTOR LIMITED Announces Receipt of Nasdaq Staff Delisting DeterminationGUANGZHOU, China, Oct. 9, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (NASDAQ:POM), a digital healthcare company focused on advancing AI-enabled healthcare solutions and predictive healthcare capabilities, today announced that it received a staff determination letter (the "Letter") from the Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") on October 6, 2026.The Letter notified the Company that the closing bid price of the Company's American depositary shares (the "ADSs") had been below $1.00 per share for 30 consecutive business days, from August 24, 2026 through October 5, 2026. As a result, the Company is not in compliance
- SECSEC Form 6-K filed by POMDOCTOR LIMITED6-K - POMDOCTOR Ltd (0001877971) (Filer)
- SECSEC Form 6-K filed by POMDOCTOR LIMITED6-K - POMDOCTOR Ltd (0001877971) (Filer)
- PRPOMDOCTOR LIMITED Accelerates AI-Enabled Chronic Disease Management and RWD CommercializationGUANGZHOU, China, Sept. 30, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (NASDAQ:POM), a digital healthcare company focused on advancing AI-enabled healthcare solutions, today provided an update on the continued progress in the development and commercialization of its AI-enabled chronic disease management ecosystem, including further optimization of its proprietary AI chronic disease management system, expanded real-world data ("RWD") applications, and integrated in-hospital and out-of-hospital chronic disease management pilots. Pomdoctor has completed multiple rounds of optimization of its AI chronic disease management system, leveraging multidimensional real-world
- SECSEC Form 6-K filed by POMDOCTOR LIMITED6-K - POMDOCTOR Ltd (0001877971) (Filer)
- SECSEC Form 6-K filed by POMDOCTOR LIMITED6-K - POMDOCTOR Ltd (0001877971) (Filer)
- PRPOMDOCTOR LIMITED Highlights Differentiated "Hardware + AI + Payment" Healthcare Infrastructure ModelGUANGZHOU, China, Sept. 24, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (NASDAQ: POM), a digital healthcare company focused on advancing AI-enabled healthcare solutions, today highlighted its differentiated "hardware + AI + payment" infrastructure model. The Company believes this integrated approach distinguishes it from traditional internet healthcare platforms and positions Pomdoctor to evolve into a comprehensive digital healthcare technology infrastructure provider. While conventional internet healthcare platforms typically operate in silos, focusing on discrete services such as online consultations, prescription processing or pharmaceutical transactions, Pomdoc
- SECSEC Form 6-K filed by POMDOCTOR LIMITED6-K - POMDOCTOR Ltd (0001877971) (Filer)
- PRPOMDOCTOR LIMITED to Participate in H.C. Wainwright's 28th Annual Global Investment ConferenceVirtual company presentation will be available beginning September 11, 2026, at 7:00 a.m. ETGUANGZHOU, China, Sept. 10, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (NASDAQ:POM), a digital healthcare company focused on advancing AI-enabled healthcare solutions, today announced that it will participate in the 28th Annual H.C. Wainwright Global Investment Conference, taking place September 14 through September 16, 2026, at the Lotte New York Palace Hotel in New York City. A pre-recorded presentation from the Company as part of the conference will be available on demand beginning Friday, September 11, 2026, at 7:00 a.m. ET. The Company also made available the investor p
- SECSEC Form 6-K filed by POMDOCTOR LIMITED6-K - POMDOCTOR Ltd (0001877971) (Filer)
- SECSEC Form 6-K filed by POMDOCTOR LIMITED6-K - POMDOCTOR Ltd (0001877971) (Filer)
- PRPOMDOCTOR LIMITED Initiates U.S. Market Preparation and Unveils Expansion StrategyGUANGZHOU, China, Aug. 27, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (NASDAQ:POM), a digital healthcare company focused on advancing AI-enabled healthcare solutions, today announced the formal initiation of its U.S. market entry preparations, marking a decisive advancement in its global growth strategy. As part of the initiative, Pomdoctor has recently commenced recruitment for core U.S.-based leadership and operational roles, completed an initial assessment of the U.S. healthcare market, and begun structuring a dedicated local compliance and regulatory framework. Concurrently, the Company is advancing product localization efforts and engaging in exploratory discu
- SECSEC Form 6-K filed by POMDOCTOR LIMITED6-K - POMDOCTOR Ltd (0001877971) (Filer)
- PRPOMDOCTOR LIMITED Highlights Healthcare Intelligence Flywheel as a Self-Reinforcing Growth EngineGUANGZHOU, China, Aug. 10, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (NASDAQ: POM), a digital healthcare company focused on advancing AI-enabled healthcare solutions and predictive healthcare capabilities, today highlighted its healthcare intelligence flywheel, a closed-loop growth model that integrates AI, wearable devices, healthcare data, professional medical services, and insurance payment networks. The Company believes this model enables each healthcare service cycle to generate incremental data, continuously strengthen AI analytics, enhance service personalization, and boost user engagement. As these capabilities reinforce one another with minimal manual int
POM FAQ
9 questionsWhat is the latest news on POM?
In the last 30 days Quantisnow tracked 10 wire items for POM: 6 press releases and news items and 4 SEC filings. The most recent was published on November 11, 2026.What is POM revenue?
POMDOCTOR LIMITED (POM) reported CN¥399.91M of revenue for fiscal 2025 (ended Dec 31, 2025). That is up 16.7% from the year before.Is POM profitable?
No. POMDOCTOR LIMITED reported a net loss of CN¥212.58M for fiscal 2025 (ended Dec 31, 2025).How much cash and debt does POM have?
POMDOCTOR LIMITED reported CN¥9.58M in cash and cash equivalents and CN¥81.82M of debt on its most recent balance sheet in SEC filings.Where does POM stock trade?
POMDOCTOR LIMITED (POM) is listed on NASDAQ.What sector and industry is POM in?
POMDOCTOR LIMITED operates in the Consumer Discretionary sector, Other Specialty Stores industry.When did POMDOCTOR LIMITED go public?
POMDOCTOR LIMITED (POM) completed its IPO in 2025.What companies are similar to POM?
Notable peers in the same industry include DKS (Dick's Sporting Goods Inc), ASO (Academy Sports and Outdoors Inc.), BBWI (Bath & Body Works Inc.), FCFS (FirstCash Holdings Inc.), BOBS (Bob's Discount Furniture Inc.). Compare POM side-by-side with any of them on Quantisnow.How can I track POM on Quantisnow?
Quantisnow aggregates POMDOCTOR LIMITED's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow POM to receive live email and push alerts on every new disclosure.